JP2007530542A - Hmb組成物及びその使用 - Google Patents
Hmb組成物及びその使用 Download PDFInfo
- Publication number
- JP2007530542A JP2007530542A JP2007504991A JP2007504991A JP2007530542A JP 2007530542 A JP2007530542 A JP 2007530542A JP 2007504991 A JP2007504991 A JP 2007504991A JP 2007504991 A JP2007504991 A JP 2007504991A JP 2007530542 A JP2007530542 A JP 2007530542A
- Authority
- JP
- Japan
- Prior art keywords
- hmb
- composition
- slurry
- protein
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Abstract
Description
タンパク質キナーゼCは、カルシウム及び脂質により活性化されるセリン−スレオニンキナーゼのファミリーであり、多くの細胞内シグナル伝達カスケードにおいて重要な役割を担う。少なくとも12個の異なるPKCアイソタイプがあり、それらはその一次構造及び生化学的特性に基づいて3つのクラスへ分類される(CA Carter:“Protein kinase C as a drug target:Implications for drug or diet prevention and treatmento of cancer.”Current Drug Targets 1: 163−183 (2000))。これらは、活性化のためにジアシルグリセロール、ホスファチジルセリン及びカルシウムを要する従来型(cPKCα、βI、βII及びγ)、ジアシルグリセロール及びホスファチジルセリンを要するがカルシウムとは無関係の新規型(nPKCδ、ε、η、θ及びμ)、並びにカルシウム及びジアシルグリセロールとは無関係の非定型(aPKCλ、τ及びζ)である。
核因子κB(NFκB)は、哺乳類細胞の幅広い種類で見られる転写因子のファミリーである。成熟分子は、次の5つの遺伝子産物(RelA (p65)、p50、RelB、c−Rel及びp52)の1つ又は2つから生成されるホモ二量体又はヘテロ二量体であり、そのもっとも共通のものはRelA及びp50の二量体である。非活性化条件下で、NFκBは、阻害性タンパク質IκBαとの会合によって、サイトゾルに局在化する。上流のシグナル伝達はIκBキナーゼを包含し、結合したIκBαのリン酸化はNFκBからのその放出を生じ、後者を核へと転移させ、特異的遺伝子転写を活性化させる。リン酸化したIκBαはユビキチン−プロテオソーム経路によって分解される。
Claims (21)
- HMB、HMBの塩、これらの代謝産物又は誘導体を投与することを含む、タンパク質キナーゼC、核因子κB、ユビキチン連結酵素及び26Sプロテアソームの構成要素からなる群から選択される構成要素の発現及び/又は活性を下方制御することによる、患者における疾病状態の予防又は治療のための方法。
- HMB、HMBの塩、これらの代謝産物又は誘導体の投与がタンパク質キナーゼCの発現及び/又は活性を下方制御する、請求項1に記載の方法。
- HMB、HMBの塩、これらの代謝産物又は誘導体の投与が核因子κBの発現及び/又は活性を下方制御する、請求項1に記載の方法。
- HMB、HMBの塩、これらの代謝産物又は誘導体の投与がユビキチン連結酵素の発現及び/又は活性を下方制御する、請求項1に記載の方法。
- HMB、HMBの塩、これらの代謝産物又は誘導体の投与が26Sプロテアソームの構成要素の発現及び/又は活性を下方制御する、請求項1に記載の方法。
- L−カルニチン、遊離アミノ酸を実質的に欠如する大型中性アミノ酸で強化されたアミノ窒素源、ω−3脂肪酸及び難消化性オリゴ糖からなる群から選択される構成要素の少なくとも1つがHMB又はHMBの塩との組み合わせで投与される、請求項1に記載の方法。
- 疾病状態が癌、カヘキシー、年齢関連消耗、長期入院と関連した消耗、HIV/エイズ、関節炎、外傷、肝疾患、クローン病、IBD、腎不全及びCOPDからなる群から選択される、請求項1に記載の方法。
- 疾病がカヘキシーである、請求項7に記載の方法。
- a.HMB、HMBの塩、これらの代謝産物又は誘導体、
b.カルニチン、
c.大型中性アミノ酸で強化されたアミノ窒素源
を含み、遊離アミノ酸を実質的に欠如する組成物。 - HMBがHMBナトリウム、HMBカリウム、HMBマグネシウム、HMBクロム、HMBカルシウム、HMBアルカリ金属、HMBアルカリ土類金属及びHMBラクトンからなる群から選択される、請求項9に記載の組成物。
- ω−3脂肪酸をさらに含む、請求項9に記載の組成物。
- 前記ω−3脂肪酸がエイコサペンタエン酸及びドコサヘキサエン酸からなる群から選択される、請求項11に記載の組成物。
- 前記大型中性アミノ酸がアミノ窒素源の少なくとも10%である、請求項9に記載の組成物。
- 前記遊離アミノ酸が組成物の0.4g/回未満である、請求項9に記載の組成物。
- カルニチンの2g未満/回をさらに含む、請求項9に記載の組成物。
- FOSの少なくとも1g/回をさらに含む、請求項9に記載の組成物。
- ビタミン、ミネラル及び微量ミネラルからなる群から選択される栄養素をさらに含む、請求項9に記載の組成物。
- a.HMBカルシウムの約2g/lから10g/lまで、
b.ω−3脂肪酸の少なくとも1g/l、
c.カルニチンの約1g/lから約8g/lまで、
d.FOSの約1g/lから約25g/lまで、
大型中性アミノ酸で強化されたアミノ窒素源を含む組成物であり、前記アミノ窒素源が大型中性アミノ酸の約10重量%から60重量%までを含み、及び前記組成物が遊離アミノ酸を実質的に欠如する組成物。 - 組成物がヒト又は動物へ投与される、請求項9に記載の組成物。
- 組成物が食事性サプリメント、食事置換物、栄養バー、咀嚼物又は咬合物及び飲料からなる群から選択される、請求項9に記載の組成物。
- 請求項9に記載の組成物を患者へ投与することを含む、患者の疾病関連消耗を治療する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/810,762 | 2004-03-26 | ||
US10/810,762 US20050215640A1 (en) | 2004-03-26 | 2004-03-26 | HMB compositions and uses thereof |
PCT/US2005/007951 WO2005102301A2 (en) | 2004-03-26 | 2005-03-14 | Hydroxymethylbutyrate compositions and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012139422A Division JP5732437B2 (ja) | 2004-03-26 | 2012-06-21 | Hmb組成物及びその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007530542A true JP2007530542A (ja) | 2007-11-01 |
JP5145033B2 JP5145033B2 (ja) | 2013-02-13 |
Family
ID=34990887
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007504991A Active JP5145033B2 (ja) | 2004-03-26 | 2005-03-14 | Hmb組成物及びその使用 |
JP2012139422A Active JP5732437B2 (ja) | 2004-03-26 | 2012-06-21 | Hmb組成物及びその使用 |
JP2015045519A Pending JP2015147773A (ja) | 2004-03-26 | 2015-03-09 | Hmb組成物及びその使用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012139422A Active JP5732437B2 (ja) | 2004-03-26 | 2012-06-21 | Hmb組成物及びその使用 |
JP2015045519A Pending JP2015147773A (ja) | 2004-03-26 | 2015-03-09 | Hmb組成物及びその使用 |
Country Status (15)
Country | Link |
---|---|
US (9) | US20050215640A1 (ja) |
EP (3) | EP2444082B1 (ja) |
JP (3) | JP5145033B2 (ja) |
KR (2) | KR20130010912A (ja) |
CN (1) | CN101212961A (ja) |
AU (1) | AU2005235133B2 (ja) |
BR (1) | BRPI0509017A (ja) |
CA (2) | CA2807787C (ja) |
EC (1) | ECSP066873A (ja) |
ES (2) | ES2699161T3 (ja) |
HK (1) | HK1155972A1 (ja) |
IL (1) | IL178039A0 (ja) |
MX (1) | MXPA06010922A (ja) |
TW (1) | TWI369981B (ja) |
WO (1) | WO2005102301A2 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012518635A (ja) * | 2009-02-24 | 2012-08-16 | リター ファーマシューティカルズ インコーポレイテッド | プレバイオティック製剤および使用方法 |
JP2013515009A (ja) * | 2009-12-18 | 2013-05-02 | メタボリック・テクノロジーズ,インコーポレーテッド | β−ヒドロキシ−β−メチル酪酸塩(HMB)の改善された投与方法 |
JP2013517806A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | 噴霧乾燥hmbを含む栄養粉末 |
JP2013517804A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | カルシウムhmbおよび可溶性タンパク質を含む栄養エマルション |
JP2013517805A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | 無菌包装されているhmbを含む栄養液 |
JP2013517808A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | カルシウムhmbを含む栄養エマルジョン |
JP2013517807A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | Hmbを含有するプラスチック包装栄養液剤 |
JP2013528060A (ja) * | 2010-06-10 | 2013-07-08 | アボット・ラボラトリーズ | カルシウムhmbおよび可溶性タンパク質を含む実質的に清澄な栄養液体 |
JP2013136587A (ja) * | 2005-12-19 | 2013-07-11 | Abbott Lab | 1型および2型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用 |
JP2014509842A (ja) * | 2011-02-07 | 2014-04-24 | アボット・ラボラトリーズ | β−ヒドロキシ−β−メチルブチラートを含む栄養製品 |
JP2015107063A (ja) * | 2013-12-03 | 2015-06-11 | 小林香料株式会社 | Hmbを含有する酸性飲料 |
JP2015530412A (ja) * | 2012-09-21 | 2015-10-15 | アボット・ラボラトリーズAbbott Laboratories | カルシウムβ−ヒドロキシ−β−メチルブチレート、タンパク質および低レベルの電解質を含む栄養組成物 |
JP2016505023A (ja) * | 2013-01-15 | 2016-02-18 | ニューサート サイエンシーズ, インコーポレイテッド | 肺の状態の処置 |
US9592248B2 (en) | 2009-02-24 | 2017-03-14 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
JP2019507727A (ja) * | 2016-01-13 | 2019-03-22 | メタボリック・テクノロジーズ,インコーポレーテッド | 関節安定性のためのβ−ヒドロキシ−β−メチルブチレート(HMB)の組成物および使用方法 |
JP2020103214A (ja) * | 2018-12-28 | 2020-07-09 | 日油株式会社 | β−ヒドロキシ−β−メチル酪酸、タンパク質、及び液状油脂を含有する液状栄養組成物 |
JP2021069308A (ja) * | 2019-10-30 | 2021-05-06 | 小林製薬株式会社 | 経口組成物 |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
PL371081A1 (pl) * | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
US9358242B2 (en) * | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9539224B2 (en) | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
DK2381784T3 (en) | 2008-12-09 | 2018-10-22 | Metabolic Tech Inc | Nutritional intervention to improve muscle function and strength |
US9770424B2 (en) | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
PL2424356T3 (pl) | 2009-04-29 | 2018-03-30 | Amarin Pharmaceuticals Ireland Limited | Stabilna farmaceutyczna kompozycja i sposoby jej stosowania |
EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
CA3026006C (en) | 2009-06-15 | 2021-09-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
MX2012003555A (es) | 2009-09-23 | 2012-07-03 | Amarin Corp Plc | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. |
CN101704736A (zh) * | 2009-10-30 | 2010-05-12 | 黄再新 | β-羟基-β-甲基丁酸生产过程中氯气逸出时的应急处理方法 |
US8490829B2 (en) | 2009-11-24 | 2013-07-23 | Pepsico, Inc. | Personalized beverage dispensing device |
US8335592B2 (en) | 2009-11-24 | 2012-12-18 | Pepsico, Inc. | Beverage dispensing device |
US9754437B2 (en) * | 2009-11-24 | 2017-09-05 | Pepsico, Inc. | Automated beverage formulation |
US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
EP2444083A1 (en) * | 2010-10-21 | 2012-04-25 | Nestec S.A. | Cysteine and food intake |
EP2646013A4 (en) | 2010-11-29 | 2014-03-26 | Amarin Pharma Inc | COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
CN103338658A (zh) * | 2010-12-22 | 2013-10-02 | 雅培制药有限公司 | 含有β-羟基-β甲基丁酸钙和共轭亚油酸的营养型产品 |
JP2014506254A (ja) * | 2010-12-27 | 2014-03-13 | アボット・ラボラトリーズ | β−ヒドロキシ−β−メチルブチレートを用いる廃用期間後の筋肉回復を促進させるための方法 |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
EP2675298A1 (en) | 2011-02-17 | 2013-12-25 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
SG193246A1 (en) * | 2011-03-31 | 2013-10-30 | Nestec Sa | Nutritional compositions for increasing arginine levels and methods of using same |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US20140256980A1 (en) * | 2011-08-15 | 2014-09-11 | Abbott Laboratories | Process for manufacturing hmb and salts thereof |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
ES2421187B1 (es) * | 2012-02-23 | 2014-11-26 | Abbott Laboratories | Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato |
US20150119339A1 (en) * | 2012-06-11 | 2015-04-30 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
MX2020013922A (es) | 2012-06-29 | 2022-08-15 | Amarin Pharmaceuticals Ie Ltd | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina. |
US20140037813A1 (en) * | 2012-08-02 | 2014-02-06 | Mead Johnson Nutrition Company | Nutritional creamer composition |
DK3733171T3 (da) * | 2012-09-10 | 2024-01-29 | Metabolic Tech Llc | Sammensætninger omfattende hmb og atp samt anvendelse deraf |
SG11201502069SA (en) * | 2012-09-17 | 2015-05-28 | Abbott Lab | Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
BR112015020977A2 (pt) | 2013-03-08 | 2017-07-18 | Axiom Foods Inc | suplemento de proteína de arroz e métodos de uso do mesmo |
US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
WO2015137965A1 (en) * | 2014-03-14 | 2015-09-17 | Metabolic Technologies, Inc. | Liquids and foodstuffs containing beta-hydroxy-beta-methylbutyrate (hmb) in free acid form |
WO2014152606A2 (en) | 2013-03-14 | 2014-09-25 | Abbott Laboratories | Treatment of insulin resistance associated with prolonged physical inactivity |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150057350A1 (en) * | 2013-08-23 | 2015-02-26 | Abbott Laboratories | Fibrosis biomarkers and methods of using same |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
WO2015094925A1 (en) | 2013-12-18 | 2015-06-25 | Capsugel Belgium Nv | Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid |
WO2015094767A1 (en) * | 2013-12-18 | 2015-06-25 | Abbott Laboratories | Methods for maintaining or increasing bodyweight using decaffeinated green tea extract |
WO2015105981A2 (en) * | 2014-01-09 | 2015-07-16 | Abbott Laboratories | Conditional essentiality of hmb |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US20160184248A1 (en) * | 2014-12-15 | 2016-06-30 | University Of Central Florida Research Foundation Inc. | Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response |
MX2017015418A (es) * | 2015-06-01 | 2018-08-24 | Metabolic Tech Inc | Composiciones y metodos de uso de beta-hidroxi-beta-metilbutirato (hmb) para reducir grasa corporal. |
MX2018003289A (es) | 2015-09-16 | 2018-11-09 | Metabolic Tech Inc | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO. |
US11406609B2 (en) | 2016-01-21 | 2022-08-09 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy |
WO2017127675A1 (en) * | 2016-01-21 | 2017-07-27 | Metabolic Technololgies, Inc. | COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
CN110891982B (zh) | 2017-04-17 | 2023-12-22 | 芝加哥大学 | 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料 |
CN110868870A (zh) | 2017-05-12 | 2020-03-06 | 艾斯姆食品公司 | 大米产物及制备它们的系统和方法 |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
CN108558707A (zh) * | 2018-04-13 | 2018-09-21 | 太仓运通新材料科技有限公司 | 一种三肌酸hmb盐的制备方法 |
MA52971A (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
IL261670B (en) * | 2018-09-06 | 2019-06-30 | Tudu Holdings Ltd | Magnesium-containing formulation and uses thereof |
MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
US10888576B2 (en) | 2018-10-08 | 2021-01-12 | Metabolic Technologies, Inc. | Composition of HMB and ATP and methods of use |
CN111714616A (zh) * | 2019-07-17 | 2020-09-29 | 江苏西宏生物医药有限公司 | 一种用于抗肿瘤的组合物 |
JP2023519170A (ja) * | 2020-03-12 | 2023-05-10 | アボット・ラボラトリーズ | 下痢または腸の炎症状態を治療する方法 |
US20210393559A1 (en) * | 2020-06-17 | 2021-12-23 | Metabolic Technologies, LLC | Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise |
CA3189075A1 (en) * | 2020-10-30 | 2022-05-05 | Pascal STUELSATZ | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for treating sarcopenia and frailty |
CA3191716A1 (en) * | 2020-10-30 | 2022-05-05 | Pascal STUELSATZ | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for treating cachexia or precachexia |
MX2023004559A (es) * | 2020-10-30 | 2023-05-04 | Nestle Sa | Composiciones que contienen nicotinamida y vitamina b6 y metodos de uso de tales composiciones para promover el crecimiento muscular. |
CA3195509A1 (en) * | 2020-10-30 | 2022-05-05 | Pascal STUELSATZ | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for rehabilitation |
WO2023031226A1 (en) * | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of branched chain fatty acids (bcfas) for the treatment of intestinal inflammation |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4742081A (en) * | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
JPH07507569A (ja) * | 1992-12-23 | 1995-08-24 | アイオワ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | ヒトの窒素保持の促進方法 |
JPH09121809A (ja) * | 1995-08-03 | 1997-05-13 | B Braun Melsungen Ag | 栄養用調製物 |
WO1998004253A1 (en) * | 1996-07-26 | 1998-02-05 | Beale Paxton K | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
JPH11508282A (ja) * | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | 悪液質および食欲不振の予防および治療方法 |
US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
JP2001288107A (ja) * | 2000-04-10 | 2001-10-16 | Snow Brand Milk Prod Co Ltd | 癌化学療法に伴う副作用軽減剤 |
JP2002518440A (ja) * | 1998-06-23 | 2002-06-25 | アイオワ ステイト ユニヴァースティ リサーチ ファウンデイション インコーポレイテッド | β−ヒドロキシ−β−メチル酪酸および少なくとも1つのアミノ酸を含む組成物および使用法 |
JP2002521428A (ja) * | 1998-07-30 | 2002-07-16 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | L−カルニチンおよびそのアルカノイル誘導体の、抗癌作用を有する医薬品の製造のための使用 |
JP2003137790A (ja) * | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | β−2,1(β2→β1)結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬 |
JP2004507479A (ja) * | 2000-08-29 | 2004-03-11 | ロンザ ア−ゲ− | 粒状化可能な混合物の調製方法及びカルニチン・マグネシウム・ヒドロキシクエン酸塩 |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US597650A (en) | 1898-01-18 | morris | ||
US3408210A (en) | 1965-06-14 | 1968-10-29 | Wilbert A. Heyman | Dehydration of foods |
US3542560A (en) | 1967-12-06 | 1970-11-24 | American Home Prod | Infant formula with fat composition like human milk |
GB1446965A (en) | 1974-02-14 | 1976-08-18 | Agricultural Vegetable Prod | Preparation of food products |
US4104290A (en) | 1975-02-07 | 1978-08-01 | H.L.S. Ltd., Industrial Engineering Company | Process for separating oils and fats into liquid and solid fractions |
US4311645A (en) | 1980-03-24 | 1982-01-19 | Hoffmann-La Roche Inc. | Synthesis of SRS-active compounds |
US4871768A (en) | 1984-07-12 | 1989-10-03 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
US4866040A (en) | 1986-01-06 | 1989-09-12 | Alfred Stracher | Aminocarnitine directed pharmaceutical agents |
DE3620433A1 (de) | 1986-06-18 | 1987-12-23 | Boehringer Ingelheim Kg | Verwendung von 2-(n-2,6-dichlorphenyl-n-allyl-amino)-imidazolin-(2) als cytoprotektives mittel |
ES2052066T3 (es) | 1988-10-31 | 1994-07-01 | Sandoz Nutrition Ltd | Mejoras en o relacionadas con compuestos organicos. |
US5000975A (en) | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
US5157022A (en) | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
US5087472A (en) * | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
US4992470A (en) * | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
US5167957A (en) | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
US5601860A (en) | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
FR2674102B1 (fr) | 1991-03-18 | 1994-05-20 | Meiji Seika Kaisha Ltd | Aliment pour porcs et methode d'elevage des porcs utilisant cet aliment. |
US5085883A (en) | 1991-06-27 | 1992-02-04 | Abbott Laboratories | Blend of dietary fiber for nutritional products |
US5171442A (en) | 1991-10-18 | 1992-12-15 | Nakshbendi Ghassan F | Water purification apparatus |
US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
WO1994006417A1 (en) * | 1992-09-16 | 1994-03-31 | Iowa State University Research Foundation, Inc. | Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol |
US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
JP2761294B2 (ja) | 1993-05-13 | 1998-06-04 | ロデルス−クロクラーン | エステル交換トリグリセリドブレンド由来のヒト母乳脂肪代用品 |
US6136858A (en) | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
US5952314A (en) | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
US5780451A (en) | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US5444054A (en) | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
US5576287A (en) | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
KR0140248B1 (ko) | 1995-03-23 | 1998-06-15 | 한상기 | 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법 |
US5641531A (en) | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
AU1335697A (en) | 1995-12-15 | 1997-07-03 | Procter & Gamble Company, The | Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems and low levels of xanthan gum |
US6165518A (en) | 1996-04-11 | 2000-12-26 | Loders Croklaan B.V. | Free flowing fat compositions |
US7504376B2 (en) | 1996-08-12 | 2009-03-17 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
DE29707308U1 (de) | 1997-04-23 | 1997-06-26 | Kunz Armin | Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus |
US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
US6103764A (en) * | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
US6194379B1 (en) | 1998-05-01 | 2001-02-27 | Abbott Laboratories | Elemental enteral formula |
US6475539B1 (en) | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
JP4175698B2 (ja) | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
US5976550A (en) * | 1998-11-20 | 1999-11-02 | Engel; Peter H. | Dietary food supplement |
US20010008641A1 (en) * | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
JP3973786B2 (ja) | 1998-12-28 | 2007-09-12 | 松下電器産業株式会社 | スパッタリング方法及び装置 |
US6294206B1 (en) | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
US6291525B1 (en) | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
CA2388733C (en) | 1999-10-18 | 2012-09-18 | Muscletech Research And Development, Inc. | Food supplement for increasing lean mass and strength |
GB9929919D0 (en) | 1999-12-17 | 2000-02-09 | Hannah Research Inst The | Calcium phosphate nanoclusters and their applications |
US6521591B1 (en) | 2000-02-10 | 2003-02-18 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
US7250397B2 (en) | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
WO2001077271A2 (en) | 2000-04-06 | 2001-10-18 | Conlinco, Inc. | Conjugated linoleic acid compositions |
US6420342B1 (en) | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
US20050106219A1 (en) | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
BR0112913A (pt) | 2000-08-03 | 2006-02-21 | Univ North Carolina State | aumento do desenvolvimento das espécies ovìparas por alimentação in ovo |
US20030203070A1 (en) | 2000-09-26 | 2003-10-30 | The Procter & Gamble Company | Compositions containing sorbitan monoesters |
EP1198991B1 (en) | 2000-10-20 | 2012-12-19 | Nutriz N.V: | Non-dairy products derived from rice |
AU2002233639B2 (en) | 2001-02-15 | 2007-03-01 | Adeka Corporation | Products containing $G(b)-glucan |
JP3735070B2 (ja) | 2001-03-26 | 2006-01-11 | 花王株式会社 | 容器詰乳化飲料 |
US6620427B2 (en) | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
US20030021877A1 (en) | 2001-06-13 | 2003-01-30 | Cain Frederick William | Micronised fat particles |
DE10145818C1 (de) | 2001-09-17 | 2002-10-10 | Alfill Engineering Gmbh & Co K | Sterilisiervorrichtung mit H202-Verdampfer |
GB2381451A (en) | 2001-11-01 | 2003-05-07 | New Technology Res Ltd | Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect |
EP2261312A1 (en) | 2001-12-12 | 2010-12-15 | Martek Biosciences Corporation | Extraction and Winterization of Lipids from Oilseed and Microbial Sources |
US7168581B2 (en) | 2001-12-21 | 2007-01-30 | Rexam Medical Packaging Inc. | Closure for a retort processed container having a peelable seal |
DE10163676A1 (de) | 2001-12-21 | 2003-07-10 | Phenion Gmbh & Co Kg | Verwendung von Hyperforin oder Extrakten aus Johanniskraut gegen anaphylaktische Schockzustände oder Osteoporose |
US20030165579A1 (en) | 2002-02-27 | 2003-09-04 | Chih-Hui Lin | Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers |
ATE361910T1 (de) | 2002-04-23 | 2007-06-15 | Aventis Pharma Inc | 3-(pyridinyl-amino)-1h-indol-2-carbonsäure- verbindungen als inhibitoren der interleukin-4 genexpression |
SE0201581D0 (sv) | 2002-05-29 | 2002-05-29 | Scandinavian Biotechnology Res | New improved acyltransferase |
US20040013787A1 (en) | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
US20040048925A1 (en) | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20040106678A1 (en) | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
US7332178B2 (en) | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
FR2856596B1 (fr) | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
WO2005035557A2 (en) | 2003-10-14 | 2005-04-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
IL158555A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
ES2314485T3 (es) | 2003-12-24 | 2009-03-16 | N.V. Nutricia | Composiciones que comprenden acido pantotenico o derivados del mismo y su uso para estimular el apetito. |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
US20050249650A1 (en) | 2004-05-07 | 2005-11-10 | Fmc Technologies, Inc. | Immersion retort |
AU2005282331A1 (en) | 2004-09-09 | 2006-03-16 | Nestec S.A. | Nutritional products having improved quality and methods and systems regarding same |
WO2006031699A2 (en) | 2004-09-10 | 2006-03-23 | Diversa Corporation | Compositions and methods for making and modifying oils |
PL371081A1 (pl) | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
US8067052B2 (en) | 2005-02-25 | 2011-11-29 | Siddharth Shastri | Nutritional composition and a container for the convenient transport and storage of the nutritional composition |
CA2537452C (en) | 2005-03-09 | 2013-12-24 | Abbott Laboratories | Concentrated human milk fortifier liquid |
BRPI0609904A2 (pt) | 2005-04-27 | 2010-05-11 | Enzymotec Ltd | substitutos da gordura do leite humano |
CN101163416A (zh) | 2005-06-06 | 2008-04-16 | 布里斯托尔-迈尔斯斯奎布公司 | 低肌醇六磷酸婴儿配方食品 |
RU2385647C2 (ru) | 2005-08-26 | 2010-04-10 | Нестек С.А. | Питание для пациентов, страдающих ожирением |
MY147363A (en) | 2005-09-20 | 2012-11-30 | Nestec Sa | Water dispersible composition and method for preparing same |
CA2625338A1 (en) | 2005-10-07 | 2007-06-14 | Ocean Nutrition Canada Ltd. | Salts of fatty acids and methods of making and using thereof |
WO2007056176A2 (en) | 2005-11-03 | 2007-05-18 | Southwest Immunology, Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
WO2007075605A2 (en) | 2005-12-19 | 2007-07-05 | Abbott Laboratories | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type and type 2 cytokine production |
ES2346802T3 (es) | 2006-01-31 | 2010-10-20 | Nestec S.A. | Composicion nutritiva para bebes con poco peso al nacimiento. |
US20080119552A1 (en) | 2006-11-17 | 2008-05-22 | Novus International Inc. | Matrix-embedded compositions having organic acids and fatty acids |
US20080194407A1 (en) | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
US8029830B2 (en) | 2008-04-18 | 2011-10-04 | Nuvocare Health Services Inc. | Composition and method for promoting internal health and external appearance |
MX2010012171A (es) | 2008-05-21 | 2010-11-30 | Stokely Van Camp Inc | Bebida de recupercion a base de leche. |
DK2381784T3 (en) | 2008-12-09 | 2018-10-22 | Metabolic Tech Inc | Nutritional intervention to improve muscle function and strength |
JP2009155336A (ja) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | 治療剤 |
US20090312419A1 (en) | 2009-08-12 | 2009-12-17 | Kneller Bruce W | CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
PL217815B1 (pl) | 2009-12-14 | 2014-08-29 | Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością | Napój izotoniczny z chelatami |
CN101785566A (zh) | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动饮料 |
SG182812A1 (en) | 2010-01-29 | 2012-09-27 | Abbott Lab | Nutritional emulsions comprising calcium hmb |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
US10869843B2 (en) | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
JP2014506254A (ja) | 2010-12-27 | 2014-03-13 | アボット・ラボラトリーズ | β−ヒドロキシ−β−メチルブチレートを用いる廃用期間後の筋肉回復を促進させるための方法 |
WO2012097061A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for improving skeletal muscle protein metabolism |
TW201320908A (zh) | 2011-10-13 | 2013-06-01 | Abbott Lab | 包含β-丙胺酸之營養產品 |
WO2013170189A1 (en) | 2012-05-11 | 2013-11-14 | Abbott Laboratories | Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow |
US20150119339A1 (en) | 2012-06-11 | 2015-04-30 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
-
2004
- 2004-03-26 US US10/810,762 patent/US20050215640A1/en not_active Abandoned
- 2004-12-29 US US11/025,466 patent/US8217077B2/en active Active
-
2005
- 2005-03-14 CN CNA2005800095960A patent/CN101212961A/zh active Pending
- 2005-03-14 CA CA2807787A patent/CA2807787C/en active Active
- 2005-03-14 ES ES11187274T patent/ES2699161T3/es active Active
- 2005-03-14 BR BRPI0509017-2A patent/BRPI0509017A/pt active Search and Examination
- 2005-03-14 ES ES10186645.7T patent/ES2586402T3/es active Active
- 2005-03-14 MX MXPA06010922A patent/MXPA06010922A/es active IP Right Grant
- 2005-03-14 KR KR1020127033546A patent/KR20130010912A/ko not_active Application Discontinuation
- 2005-03-14 KR KR1020067022383A patent/KR101253063B1/ko not_active IP Right Cessation
- 2005-03-14 EP EP11187274.3A patent/EP2444082B1/en not_active Not-in-force
- 2005-03-14 JP JP2007504991A patent/JP5145033B2/ja active Active
- 2005-03-14 WO PCT/US2005/007951 patent/WO2005102301A2/en active Application Filing
- 2005-03-14 EP EP05732120A patent/EP1727534A2/en not_active Withdrawn
- 2005-03-14 AU AU2005235133A patent/AU2005235133B2/en not_active Ceased
- 2005-03-14 CA CA2560042A patent/CA2560042C/en not_active Expired - Fee Related
- 2005-03-14 EP EP10186645.7A patent/EP2301529B1/en not_active Not-in-force
- 2005-03-25 TW TW094109357A patent/TWI369981B/zh active
-
2006
- 2006-09-12 IL IL178039A patent/IL178039A0/en unknown
- 2006-09-22 EC EC2006006873A patent/ECSP066873A/es unknown
-
2007
- 2007-05-22 HK HK11110329.8A patent/HK1155972A1/zh not_active IP Right Cessation
-
2012
- 2012-01-11 US US13/348,024 patent/US8785496B2/en not_active Expired - Lifetime
- 2012-01-11 US US13/347,956 patent/US8785495B2/en not_active Expired - Lifetime
- 2012-01-11 US US13/347,985 patent/US20120177752A1/en not_active Abandoned
- 2012-01-11 US US13/347,877 patent/US8778993B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/348,035 patent/US8778994B2/en not_active Expired - Lifetime
- 2012-01-11 US US13/348,026 patent/US8609725B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,978 patent/US20120189715A1/en not_active Abandoned
- 2012-06-21 JP JP2012139422A patent/JP5732437B2/ja active Active
-
2015
- 2015-03-09 JP JP2015045519A patent/JP2015147773A/ja active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4742081A (en) * | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
JPH07507569A (ja) * | 1992-12-23 | 1995-08-24 | アイオワ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | ヒトの窒素保持の促進方法 |
JPH09121809A (ja) * | 1995-08-03 | 1997-05-13 | B Braun Melsungen Ag | 栄養用調製物 |
JPH11508282A (ja) * | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | 悪液質および食欲不振の予防および治療方法 |
WO1998004253A1 (en) * | 1996-07-26 | 1998-02-05 | Beale Paxton K | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
JP2002518440A (ja) * | 1998-06-23 | 2002-06-25 | アイオワ ステイト ユニヴァースティ リサーチ ファウンデイション インコーポレイテッド | β−ヒドロキシ−β−メチル酪酸および少なくとも1つのアミノ酸を含む組成物および使用法 |
JP2002521428A (ja) * | 1998-07-30 | 2002-07-16 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | L−カルニチンおよびそのアルカノイル誘導体の、抗癌作用を有する医薬品の製造のための使用 |
JP2001288107A (ja) * | 2000-04-10 | 2001-10-16 | Snow Brand Milk Prod Co Ltd | 癌化学療法に伴う副作用軽減剤 |
JP2004507479A (ja) * | 2000-08-29 | 2004-03-11 | ロンザ ア−ゲ− | 粒状化可能な混合物の調製方法及びカルニチン・マグネシウム・ヒドロキシクエン酸塩 |
JP2003137790A (ja) * | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | β−2,1(β2→β1)結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬 |
Non-Patent Citations (2)
Title |
---|
"Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-me", AMERICAN JOURNAL OF SURGERY, vol. 183, no. 4, JPN6011032121, 2002, pages 471 - 9, ISSN: 0001946107 * |
CLARK,R.H. ET AL.: "Nutritional treatment for acquired immunodeficiency virus-associated wasting using β-hydroxy β-met", JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, vol. 24, no. 3, JPN5007004235, May 2000 (2000-05-01), pages 133 - 9, XP009004307, ISSN: 0001946108 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013136587A (ja) * | 2005-12-19 | 2013-07-11 | Abbott Lab | 1型および2型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用 |
US9775860B2 (en) | 2009-02-24 | 2017-10-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9592248B2 (en) | 2009-02-24 | 2017-03-14 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9579340B2 (en) | 2009-02-24 | 2017-02-28 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9370532B2 (en) | 2009-02-24 | 2016-06-21 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
JP2012518635A (ja) * | 2009-02-24 | 2012-08-16 | リター ファーマシューティカルズ インコーポレイテッド | プレバイオティック製剤および使用方法 |
JP2016065069A (ja) * | 2009-02-24 | 2016-04-28 | リター ファーマシューティカルズ インコーポレイテッド | プレバイオティック製剤および使用方法 |
JP2016026181A (ja) * | 2009-12-18 | 2016-02-12 | メタボリック・テクノロジーズ,インコーポレーテッド | β−ヒドロキシ−β−メチル酪酸塩(HMB)の改善された投与方法 |
JP2013515009A (ja) * | 2009-12-18 | 2013-05-02 | メタボリック・テクノロジーズ,インコーポレーテッド | β−ヒドロキシ−β−メチル酪酸塩(HMB)の改善された投与方法 |
JP2013517807A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | Hmbを含有するプラスチック包装栄養液剤 |
JP2013517804A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | カルシウムhmbおよび可溶性タンパク質を含む栄養エマルション |
JP2015163074A (ja) * | 2010-01-29 | 2015-09-10 | アボット・ラボラトリーズAbbott Laboratories | カルシウムhmbおよび可溶性タンパク質を含む栄養エマルション |
JP2013517806A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | 噴霧乾燥hmbを含む栄養粉末 |
JP2013517808A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | カルシウムhmbを含む栄養エマルジョン |
JP2013517805A (ja) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | 無菌包装されているhmbを含む栄養液 |
JP2013528060A (ja) * | 2010-06-10 | 2013-07-08 | アボット・ラボラトリーズ | カルシウムhmbおよび可溶性タンパク質を含む実質的に清澄な栄養液体 |
JP2014509842A (ja) * | 2011-02-07 | 2014-04-24 | アボット・ラボラトリーズ | β−ヒドロキシ−β−メチルブチラートを含む栄養製品 |
JP2015530412A (ja) * | 2012-09-21 | 2015-10-15 | アボット・ラボラトリーズAbbott Laboratories | カルシウムβ−ヒドロキシ−β−メチルブチレート、タンパク質および低レベルの電解質を含む栄養組成物 |
JP2016505023A (ja) * | 2013-01-15 | 2016-02-18 | ニューサート サイエンシーズ, インコーポレイテッド | 肺の状態の処置 |
US10039733B2 (en) | 2013-01-15 | 2018-08-07 | Nusirt Sciences, Inc. | Compositions, method, and kits for treating pulmonary conditions |
JP2015107063A (ja) * | 2013-12-03 | 2015-06-11 | 小林香料株式会社 | Hmbを含有する酸性飲料 |
JP2019507727A (ja) * | 2016-01-13 | 2019-03-22 | メタボリック・テクノロジーズ,インコーポレーテッド | 関節安定性のためのβ−ヒドロキシ−β−メチルブチレート(HMB)の組成物および使用方法 |
JP2022001586A (ja) * | 2016-01-13 | 2022-01-06 | メタボリック・テクノロジーズ,インコーポレーテッド | 関節安定性のためのβ−ヒドロキシ−β−メチルブチレート(HMB)の組成物および使用方法 |
JP7401969B2 (ja) | 2016-01-13 | 2023-12-20 | メタボリック・テクノロジーズ,インコーポレーテッド | 関節安定性のためのβ-ヒドロキシ-β-メチルブチレート(HMB)の組成物および使用方法 |
JP2020103214A (ja) * | 2018-12-28 | 2020-07-09 | 日油株式会社 | β−ヒドロキシ−β−メチル酪酸、タンパク質、及び液状油脂を含有する液状栄養組成物 |
JP7286964B2 (ja) | 2018-12-28 | 2023-06-06 | 日油株式会社 | β-ヒドロキシ-β-メチル酪酸、タンパク質、及び液状油脂を含有する液状栄養組成物 |
JP2021069308A (ja) * | 2019-10-30 | 2021-05-06 | 小林製薬株式会社 | 経口組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5732437B2 (ja) | Hmb組成物及びその使用 | |
CA2252513C (en) | Method for the prevention and treatment of cachexia and anorexia | |
CA2355247C (en) | Method for the prevention and treatment of cachexia and anorexia | |
NZ504416A (en) | Nutritional compositions including proteins, antioxidants and oil blends for the treatment of cachexia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080229 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110915 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120313 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120611 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120621 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20120827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121010 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20121030 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121120 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121126 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151130 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5145033 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |